|
|
Post by tmfbmf on Feb 25, 2020 13:14:45 GMT
Added to ATHX. Plan to continue to add if pps continues to drift lower. (Note: Also have position in ESPR. PDUFA approval date is today 2/21; FDA decision likely afterhours today, with company PR afterhours today or Monday AM. EU CHMP recently rendered positive recommendation to approve in EU. EU decision in April. IMO, FDA likely to approve... but no guarantees of course. Just figured I'd briefly mention it. If anyone has interest, we can create a separate ESPR thread.)GL all. I had a little extra cash in my acct so I bought some ESPR on your rec. Doesn't look to be any downside. Wish I got more! |
|
|
|
Post by jckrdu on Feb 25, 2020 13:47:03 GMT
Added to ATHX. Plan to continue to add if pps continues to drift lower. (Note: Also have position in ESPR. PDUFA approval date is today 2/21; FDA decision likely afterhours today, with company PR afterhours today or Monday AM. EU CHMP recently rendered positive recommendation to approve in EU. EU decision in April. IMO, FDA likely to approve... but no guarantees of course. Just figured I'd briefly mention it. If anyone has interest, we can create a separate ESPR thread.)GL all. I had a little extra cash in my acct so I bought some ESPR on your rec. Doesn't look to be any downside. Wish I got more! Tmf - I created a new thread so we can have any conversation there. thebiotechinvestor.freeforums.net/thread/1448/esperion-espr |
|
|
|
Post by lcd on Mar 9, 2020 15:54:46 GMT
Athersys is today's COVID-19 speculator's stock, currently up over 13% while the rest of the market is getting crushed.
|
|
|
|
Post by jckrdu on Mar 13, 2020 20:58:41 GMT
Bullish for Monday. Posted the below on the Reddit board earlier today...
I hear you, and I'm not married to any stock... including ATHX. But, I did add today at $1.17 because I think we'll get a tangible update on the status of the EU partnership on Monday. If Gil doesn't show that the EU partnership ball is clearly moving forward, than I agree sub $1 is on the table.
On the EU partnership, IMO Gil has got to do 1 of the 3:
1) provide an update where the guidance language is updated to something like "finalizing negotiations with a single partner"... or "late stage" discussions,
2) announce the partnership (or an MOU), or
3) announce a $10M commitment fee that they've secured as they complete the discussions.
IMO, either of those will put a floor under the pps and will likely generate more buying as the market will see a deal getting closed soon.
Note that only in a very recent presentation did Gil add the written goal to "complete/implement" partnership activities... so IMO the update Monday will show tangible positive movement in that direction. A nebulous/general update without any of the above will get sold off. I added today because I think Gil will deliver.
|
|
|
|
Post by tmfbmf on Mar 17, 2020 13:13:24 GMT
With BARDA getting involved in our ARDS treatment I think we'll announce, within a month, a small PIII trial fully funded by BARDA or some other agency. The Japan trial will augment ours. That's an open-label trial that we know is going well. I believe Healios will stop it early, in May, so Healios can apply for conditional approval. They probably won't get the full 30 patient enrollment but if the data show signs of efficacy there's no point is waiting through the summer when there are far fewer ARDS cases. I expect our trial to begin in June and take less than a year to fully enroll. (This might be wishful thinking about getting started so fast, but with this pandemic the government is desperate to look like they're doing something.)
|
|
|
|
Post by imz72 on Mar 17, 2020 13:24:08 GMT
FWIW: Dawson James (Jason Kolbert) raises price target from $11 to $12 " BUY: Highly Relevant – ARDS: MultiStem Fast TrackThe focus of the Athersys call was COVID-19 and ARDS or Acute Respiratory distress syndrome (ARDS). Athersys has been in talks with the U.S. government and possible other countries like Japan. We do see the possibility that Multistem could be utilized to treat ARDS patients which could, if successful, change the outcome and improve hospital capacity. We are adjusting our price target from $11.00 to $12.00." dawsonjames.com/wp-content/uploads/2020/03/ATHX.DJ_.3.17.2020.pdf_____________________________________________________ "Needham analyst Chad Messer maintained a Buy rating on Athersys today and set a price target of $6.00." www.smarteranalyst.com/new-blurbs/analysts-offer-insights-on-healthcare-companies-athersys-athx-sesen-bio-sesn-and-y-mabs-therapeutics-ymab/_____________________________________________________ And on this occasion - this was Healios director Gregory Bonfiglio, in panel discussion at Phacilitate 2020 on 23 January 2020: |
|
|
|
Post by morangie777 on Mar 17, 2020 16:36:40 GMT
The potential for surprise news is clearly there. BARDA, Japan, or others.
In the CC I found Gil sound overly defensive on a number of points.
Off the top of my head,
- Barda potential funding "But the 8B funding package was just announced a week or 2 ago"
- meaning of "Highly relevant", he did not manage to "sell" this as something really powerful and useful. Basically he did not give any meaningful info on this, either out of ignorance or intentionally evading the topic.
- compassionate use, or some kind of exception for covid19 - extremely defensive. Like someone who already knows that in no way they would be able to pull off delivering the supply for this.
It left some aftertaste. The long term story is intact for me, but short/mid term, the surprise news would have to be phenomenal to mitigate the slow burn from the remaining time to results and market.
I tend to believe that if for example Barda announces they would fund a covid19 Multistem trial, this is not the kind of phenomenal news needed.
glta
|
|
|
|
Post by jckrdu on Mar 17, 2020 16:53:02 GMT
I'm staying fully invested here until we see the ATHX/BARDA agreement news.
News should be out soon, and could be substantial and cause the market to value ATHX much higher.
|
|
|
|
Post by jckrdu on Mar 17, 2020 17:42:28 GMT
With BARDA getting involved in our ARDS treatment I think we'll announce, within a month, a small PIII trial fully funded by BARDA or some other agency. The Japan trial will augment ours. That's an open-label trial that we know is going well. I believe Healios will stop it early, in May, so Healios can apply for conditional approval. They probably won't get the full 30 patient enrollment but if the data show signs of efficacy there's no point is waiting through the summer when there are far fewer ARDS cases. I expect our trial to begin in June and take less than a year to fully enroll. (This might be wishful thinking about getting started so fast, but with this pandemic the government is desperate to look like they're doing something.) Exciting times Tmf. I agree an ARDS trial in the US will start quickly, and will likely include Covid19 patients that need treatment as part of this outbreak. IMO, BARDA needs to act fast. The below is from the transcript of yesterday's conference call. If they can cut thru the red tape to get the trial approved to start, they could likely get a Covid19 arm fully enrolled in a few months, given the expected number of people needing treatment in some highly populated areas. ------------------------------- "we are committed to designing and executing inappropriate clinical trial to further evaluate the safety and efficacy of MultiStem for patients with ARDS, and to advance that program as fast as we can. This trial could include evaluation of COVID-19 induced ARDS patients and such an evaluation could be conducted separately or in parallel, that will have to be definitively established in coordination with the FDA and other relevant agencies" seekingalpha.com/article/4332329-athersys-athx-ceo-gil-van-bokkelen-on-q4-2019-results-earnings-call-transcript?page=8 |
|
|
|
Post by jckrdu on Mar 18, 2020 17:36:16 GMT
Trump is holding a news conference later today (3/18) or tomorrow (3/19) where the specific and only topic is "the FDA". That conference may give us some clues regarding the content/scope/timing of the expected ATHX/BARDA agreement. In at least 1 report I read, a topic will be reducing regulatory burdens regarding vaccines and therapeutics for Covid19. Could be nothing. Could be something.
|
|
|
|
Post by jckrdu on Mar 19, 2020 21:18:34 GMT
Market liking recent FDA news to push therapeutics for Covid-19.
ATHX in the pole position to treat the most severe cases that degrade into ARDS.
ATHX/BARDA agreement coming soon which will include non-dilutive $$$ and will better define the path ahead.
|
|
|
|
Post by avtech on Mar 19, 2020 22:11:13 GMT
In the past Gil has stated that ATHX MAPC production stands in line behind other companies needing cell lines produced by Lonza. Hopefully now that the Defense Production Act can be employed the two Lonza facilities in the USA will be targeted for the ATHX MAPC line.
|
|
|
|
Post by jckrdu on Mar 22, 2020 18:29:44 GMT
Market liking recent FDA news to push therapeutics for Covid-19. ATHX in the pole position to treat the most severe cases that degrade into ARDS. ATHX/BARDA agreement coming soon which will include non-dilutive $$$ and will better define the path ahead. In response to some private messages from some not following Athersys (ATHX), below is a summary of the current situation and opportunity given the Covid-19 pandemic, from my perspective. My intent with this post is to frame things in a way that allows folks unfamiliar with ATHX to digest relevant information relatively quickly, including the near-term opportunity and risks. I've provided some links in the appendix so anyone can drill down as much as they'd like. Good luck all.
Quick Summary:
Acute Respiratory Distress Syndrome (ARDS) is the leading cause of death among Covid-19 infected patients. Athersys' MultiStem cell therapy is focused on this "critical care" market segment, has completed a Phase 2 clinical trial for ARDS with very promising results, and is the only company with Fast Track designation from the FDA for ARDS. While MultiStem is not approved for commercial use, the US Government (BARDA) is currently actively engaged with Athersys leadership to advance the MultiStem therapy as "quickly as possible", and has deemed MultiStem "Highly Relevant" to the Covid-19 outbreak. News on the path forward from Athersys/BARDA is expected at any time.
Given the urgent need which is a matter of life or death for critically afflicted patients, an important question is "How quick will the FDA & BARDA move?"
The Big Picture - Situation Analysis:
While ATHX has a deep clinical pipeline (ARDS, stroke, trauma, etc), this summary will focus on ARDS (Acute Respiratory Distress Syndrome) as the global Covid-19 pandemic has pushed that program to the forefront.
In summary, the world is racing to medically address the Covid-19 pandemic in 3 major ways, from my perspective:
Vaccines - The first "line of defense" are vaccines which aim to prevent infections, but won't be ready for 12-18 months.
Anti-Viral Treatments - Once infected, the second line of defense are anti-virals to treat the infection. Last week the FDA announced some good news where a few existing FDA approved anti-virals (approved for other diseases), are being re-purposed to treat Covid-19 patients, and evaluate their effectiveness. Per Dr. Fauci, their effectiveness against Covid-19 has not been proved.
Critical Care for Patients that Degrade and Develop ARDS / Moved to ICU and Placed on Ventilators - Even if the anti-virals and eventually vaccines have some success, a "meaningful number of people" per the Athersys CEO, will still degrade and develop ARDs. For these ARDS patients that require critical respiratory care, there are no FDA approved treatments, as the current standard of care is severely lacking and consists of placement in an ICU bed (if one is available), ventilator support (if one is available), and hope for the best. Death is a frequent outcome, and patients that survive face a difficult road to recovery as in many cases, the impacts are permanent. Treatments beyond ventilator support for the critical care patients are needed, now.
The urgency of new critical care treatments is amplified given the huge spikes in the number of patients due to Covid-19. Over the past several months we've seen China build new hospitals to attempt to meet the surge in demand. We continue to see and hear the stories of hospitals and ICUs being over-run with Covid-19 patients that are having severe respiratory issues, and are in urgent need of ICU beds and ventilators. In some cases (Italy) the physicians are making life/death decisions on who gets an ICU bed and ventilator, and who doesn't.
For COVID-19 infected Patients, ARDS is the Leading Cause of Death - According to a recent World Health Organization analysis and other clinical and epidemiological data, ARDS is the leading cause of death among COVID-19 infected patients. (Appendix - Slide #34 of Athersys Corporate Presentation)
With the global pandemic raging, is there anything out there that can help critically ill patients with severe respiratory failure needing ICU and ventilation support?
Yes, there is... but the therapy is not approved by the FDA, yet.
The Athersys Critical Care/ARDS Treatment and Clinical Trial Results: Athersys has the only ARDS treatment with Fast-Track designation by the FDA. The treatment completed a Phase 2 trial in the United States with a Phase 3 trial to start soon, and a pivotal trial is nearing completion in Japan.
As someone who has followed Athersys and their MultiStem treatment for close to a decade, its frustrating (and sad) not to see any national news discussions of their very promising MultiStem cell therapy for these critical care ARDs patients. However, due to the Covid-19 pandemic, it appears that Athersys now has the attention at the highest levels within the United States government (see BARDA link in Appendix), and they're working together to advance the program as "quickly as possible", per the Athersys CEO.
Why Do Some People Get ARDS? - After infected with Covid-19, "a pulmonary hyper-inflammatory response can occur, leading to severe pulmonary dysfunction & hospitalization". (Appendix - Slide #39 of Athersys Corporate Presentation) How does MultiStem treat ARDS? - Essentially, MultiStem helps regulate the immune system, so the hyper-inflammatory response is mitigated.
MultiStem has shown very promising Phase 2 clinical trial results, with initial 28 day and longer term 1-year follow-up data reported. A Phase 3 trial is planned in the United States, and an open-label pivotal trial is on-going and nearing completion in Japan. Some key points from the Phase 2 data is below, which is for patients with "low pulmonary function at baseline", who may be the most at risk to develop complications. (Appendix - Slides #37 and #39 of Athersys Corporate Presentation):
Saved Lives - Mortality MultiStem 25% / Mortality Placebo 50% (Half as many of the MultiStem treated patients died compared to placebo.)
ICU Capacity Increased - ICU Free Days MultiStem 11.4 / ICU Free Days Placebo 5.9 (Almost half less time in ICU.)
Ventilator Capacity Increased - Ventilator Free Days MultiStem 14.6 / Ventilator Free Days Placebo 8 (Almost half less time on Ventilator.) Improved Quality of Life at 1 Year - 80% of surviving patients in MultiStem group achieved complete independence in self-care vs. 40% in placebo group
In summary, albeit a Phase 2 trial with a small data-set, Athersys' MultiStem therapy directly addressed the urgent needs of critical care patients and hospital ICU and ventilator capacity. One can easily extrapolate the above results to the current situation, and see the potential to save many lives and increase hospital capacity.
MultiStem also has an excellent safety profile as a result of 10 clinical trials conducted over 12 years where safety has been established in 6 different disease indications, for approximately 1000 trial participants, including placebo. Potential benefits are substantial, including life versus death, and far exceed any risks, in my view. So, what are we waiting for as the pandemic continues to kill and shuts down the world? That brings us to the path forward, where the highest level of the United State government now appears actively engaged.
The Path Forward:
The Path Forward - Background: Per the Athersys CEO in the 3/16/2020 press release (see appendix), here's what he stated about their ARDS program, and how its being advanced in-light of the Covid-19 outbreak, in partnership with the US Government and BARDA: (See appendix for BARDA information.)
“The importance of this program has been reinforced by the recent COVID-19 outbreak, where many patients have subsequently become critically ill with ARDS, which a recent World Health Organization analysis has confirmed is the primary cause of death for these patients. This often fatal syndrome can be induced by a range of pathogens, including COVID-19, SARS, MERS and virulent influenza.
“Other than placing patients on a ventilator, there is no effective treatment for ARDS. In January, in the early stages of the COVID-19 outbreak, as part of the U.S. Government's COVID-19 CoronaWatch program, we were approached by BARDA in its leadership role focused on expediting diagnostics, vaccines, antivirals and therapeutic treatments for these patients. After undergoing multiple reviews, we are pleased to announce that MultiStem® was designated as a “Highly Relevant” therapeutic for COVID-19 by BARDA. We now are working to expedite the further advancement of the program, which has also shown relevance to certain other areas of interest for BARDA,” added Dr. Van Bokkelen.
The Path Forward - Finalization of Athersys/BARDA Collaboration Agreement:
Per the CEO in the 3/16/2020 press release (appendix), the agreement with BARDA is being "finalized". The CEO stated “We remain highly focused on achieving our core goals and are making excellent progress. Our near-term priorities are to finalize and implement an alliance with BARDA, establish a high value collaboration around our critical care programs, and continue to advance our clinical programs, while we add additional talent and leadership to the organization and expand our capabilities,” concluded Dr. Van Bokkelen.
The Path Forward - Hints of a Broader Collaboration with BARDA, Beyond Covid-19:
Subsequent comments by the CEO have hinted at perhaps a broader collaboration with BARDA, beyond just Covid-19 impacts. The CEO noted that when new pathogens emerge (i.e. SARS, MERS, Covid-19, etc.) the world is always behind the curve racing to develop new vaccines & new anti-virals for the next illness. He notes that MultiStem could be a valuable treatment tool in the national arsenal, as it treats impacted patients with ARDS regardless of the current or future pathogen causing the illness. We're in wait-and-see mode to see what the BARDA collaboration agreement may or may not include, on this interesting and forward looking concept.
The Path Forward - Will it be Bold Enough for those with Covid-19 induced ARDS, Fighting for their Lives on a Ventilator Today? The FDA Commissioner recently stated his goal of making safe and effective therapies available to Covid-19 patients in need, as quickly as possible. Until I see the ATHX/BARDA collaboration agreement, I'm not going to pass any judgements on whether the path forward is bold enough, and whether it matches the urgency needed by patients on a ventilator who are fighting for their lives at this very moment, and the new patients who will certainly be fighting for their lives in the weeks ahead. I'll just say that MultiStem has an established safety record, and will let Jason Kolbert make the case for the FDA to immediately approve MultiStem via Emergency Authorization Use (EAU) for patients in need. Please see the appendix for Jason's TV interview.
Regardless of what the ATHX/BARDA agreement contains, I commend the Athersys CEO and management team for advancing the ARDS program over the past many years, as they recognized the importance of their treatment, and have brought it to the brink of being deployed to help thousands, perhaps hundreds of thousands of people.
Large ARDS Market Opportunity:
ARDS is not just caused by Covid-19, and afflicts approximately 500,000 patients in Europe, the United States and Japan combined annually.
An outbreak of highly infectious pathogens (e.g. SARS, Coronavirus, Influenza) that result in severe acute pulmonary disease could cause a surge in ARDS incidence.
No effective pharmaceutical or biologic treatments currently available.
Represents a multi-billion $ market opportunity.
Note: The above does not discuss Athersys even larger target markets for stroke and trauma, which are also advancing.
Major Upcoming Milestones:
Below are what I consider some major upcoming milestones I'm tracking for both the ARDS and stroke programs, which I expect to see through the remainder of 2020 and early 2021:
- Any Day - ATHX/BARDA Collaboration Agreement Announced. (Latest CEO guidance is that the agreement is being "finalized".)
- April/May - ARDS Peer-Reviewed Data Publication (Given the pandemic, this publication could have an impact. Intent to publish was noted via PR in January 2020.)
- May - ARDS Japan/Helios Trial Enrollment Completion (Helios Board member indicated May completion target at recent panel discussion.)
- June/July/August - ARDS Pivotal Trial Data Announced (Trial endpoint data is gathered 28 days after patient enrollment.)
- June/July/August - European Partnership (IMO this can come at any time, but management may feel they'll be in a stronger position to sign a deal after the Japan ARDS data is made public. Pros and cons can be argued for either approach. I have high confidence the Athersys team will maximize value.)
- September - Stroke Trial Enrollment Completion in Japan (Helios Board member indicated Sept completion target at recent panel discussion.)
- December/January - Stroke Data Japan (Stroke data expected 90-120 days after enrollment completion.)
- Any Day WILDCARD - Emergency Use Authorization (EAU) issued by FDA for MultiStem to Allow Treatments to Begin Now Based on Phase 2 Data (We can all dream.)
In some years, with lengthy clinical trials in progress there can sometimes be a news drought. 2020 is NOT one of those years.
The Risks: I hold a position in ATHX and intend to continue to hold, as I believe many value-creating milestones will unfold in 2020. However, anyone thinking of investing or increasing their position should note that biotech stocks are high-risk investments. While many risks exist, some of the key near-term risks on my radar that I monitor and continually re-assess are listed and briefly discussed below.
Risk that the Pending ATHX/BARDA Agreement Does Not Meet Market Expectations - The stock has run-up 50% over the past week from approximately $1.20 to $1.80 (March 16th to March 20th). In my opinion (IMO), at least part of this run-up is due to the market's expectation of a significant collaboration agreement with BARDA to address Covid-19. If the agreement - when announced - does not meet market expectations (in terms of funding, schedule and scope), the stock could retrace.
Is this Risk Mitigated? In my opinion, because the MultiStem therapy has a stellar safety profile, has been designated as "Highly Relevant" by BARDA, and is the only treatment for ARDS with Fast-Track designation by the FDA, I believe the MultiStem therapy will be adequately funded by BARDA to quickly advance the program to treat Covid-19 patients in need. A legitimate question is, how quick? I believe the pending ATHX/BARDA collaboration agreement will reflect the urgent needs of patients and hospital capacity.... and will reflect the dire consequences of anything less than bold action. So, I'm expecting a significant/beefy deal with BARDA, and believe the market will like what it hears. (As always, the above is my opinion. I could be wrong.)
Risk of Low Cash Position - Per their SEC filings, Athersys cash position at 12/31/2019 was approximately $35 million. They burn approximately $12 million per quarter, so by 3/31/2020 they'll have approximately $23 million in cash, plus any cash raised via their equity line with Aspire. Cash needs will increase in 2020, per SEC filings. Is this Risk Mitigated? In my opinion, the following pending activities will provide ample cash: 1) BARDA agreement - While this agreement will likely allocate funds to the ARDS program only and not general corporate needs, it should - combined with the Aspire equity line - provide an ample bridge to their next major source of cash which is, 2) European Partnership - Guidance from Athersys via slide #42 of the corporate presentation (see appendix) is "Complete evaluation / implementation of key partnering initiatives", which implies they expect a deal done before the end of 2020, so that it can be "implemented" before year end 2020. In my view, the pending BARDA agreement will create more partner interest and perhaps competition to be Athersys' partner in Europe. Lastly and in the worst case, if they feel they need to raise capital via an equity offering (dilution) before the European partnership produces cash, I'm reasonably comfortable that the BARDA agreement will cause the stock price to find a higher new floor, so that modest dilution - if needed - will bridge them to closure of the European partnership later in 2020.
Risk from Competition - Given the urgent need, there's a competitive race to find vaccines, anti-virals and therapies. Is this Risk Mitigated? Even with eventual upstream success with vaccines and anti-virals, there will always be a need for therapies in the critical care segment for ARDS. To the CEO's knowledge, Athersys is the only company with a therapy designated as Fast-Track by the FDA for ARDS. In my view, that designation serves to mitigate this risk. The fact that BARDA approached Athersys to explore ways to accelerate their ARDS timelines appears to indicate that Athersys is at the forefront. I'm going to re-assess this risk after I see the ATHX/BARDA collaboration agreement, as that agreement should let us know how quickly the MultiStem treatment will move forward. The faster Athersys, BARDA and the FDA work together to get MultiStem approved for ARDS, the more this risk will be mitigated.
Risk that soon to be released pivotal trial ARDS data from Helios (Athersys' partner in Japan) is not favorable - Data from Helios' pivotal trial treating ARDS patients with MultiStem will likely be released sometime this summer. Like all biotechnology companies, if clinical data is not positive it usually has a severe negative impact. Is this Risk Mitigated? In my view, this risk is mitigated in 3 ways: 1) The new Japanese regenerative medicine laws allow therapies to be either approved or conditionally approved based on signs of efficacy. All trial endpoints do not have to be met in order to achieve conditional approval. In my opinion, given prior trial results, biomarker analysis, and the well understood mechanism of action with MultiStem, there is a high probability that at least some signs of efficacy will be observed to allow conditional approval, at a minimum. 2) BARDA just recently gave MultiStem the "Highly Relevant" designation in the 1st quarter of this year. Before giving this designation, BARDA took a detailed look at MultiStem, which - in my opinion - included a review of all available clinical data. Since Helios' ARDS trial is open-label (meaning data is available for Helios to review) it most likely included a review of that data, as Helios and Athersys are partners. In my opinion, BARDA would not have given the "Highly Relevant" designation if the open-label data was poor. 3) At a recent company presentation, the CEO of Helios expressed confidence that the MultiStem therapy would be approved. In my view, with an open-label trial, confidence would only be expressed if the data was promising.
Conclusion: MultiStem has established an excellent safety record over an approximate 12 year period, in 10 clinical trials, for 6 different diseases, which included approximately 1000 trial patients, including placebo. (Source is clinicaltrials.gov in Appendix). The MultiStem cells do not engraft and are cleared from the body in days.
With significant efficacy reported in their Phase 2 ARDS trial, it would seem that invoking Emergency Authorization Use (EAU) for MultiStem would provide a low risk approach to give severely afflicted ARDS patients a fighting chance, while also helping address the shortage of critical care resources; ICU beds and ventilators.
Athersys is a small biotechnology company with 75 employees and a relatively small valuation of $300 million. Given the on-going pandemic, Athersys' promising MultiStem therapy to treat severely afflicted ARDS patients, and active US government/BARDA engagement with some level of funding pending and imminent, I consider it under-valued at current levels of approximately $2.00 per share.
If MultiStem is not given Emergency Authorization Use (EAU) for ARDS sometime this coming week, my next post will be the letter I send to my local and State politicians, to attempt to raise awareness and push from the bottom up.
Appendix/Links:
What is ARDS? (ATHX Video)
Plea to Allow Emergency Authorization Use (EAU) for MultiStem - Jason Kolbert Analyst Interview
Athersys Corporate Presentation (March 2020)
US Government BARDA Mission (BARDA Website)
03/16/2020 Press Release - CEO Comments - "Highly Relevant" BARDA Designation & Pending BARDA Agreement
Wall Street Titan (WST) Article on Seeking Alpha. WST is a knowledgeable biotech analyst and long-time Athersys advocate, who consistently provides well-researched articles, interviews and other content on Athersys and other biotechnology companies. This article - like all his others - is worth a read.
|
|
